Use of Phage Display technology in development of canine visceral leishmaniasis vaccine using synthetic peptide trapped in sphingomyelin/cholesterol liposomes

Parasites and Vectors

Volumn 8, Issue 1, 2015, Pages

  Toledo Machado, Christina Monerat ^a   Bueno, Lilian Lacerda ^a   Menezes Souza, Daniel ^a   Machado De Avila, Ricardo Andrez ^b   Nguyen, Christophe ^c   Granier, Claude ^c   Bartholomeu, Daniella Castanheira ^a   Chávez Olórtegui, Carlos ^a   Fujiwara, Ricardo Toshio ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^c UMR 3145 CNRS Bio Rad   (France)

Author keywords

Canine Visceral Leishmaniasis; Liposomes; Phage Display; Synthetic Peptides; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; CHOLESTEROL; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; LEISHMANIA VACCINE; LIPOSOME; SPHINGOMYELIN; SYNTHETIC PEPTIDE; PEPTIDE; PEPTIDE LIBRARY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOPANNING; BLOTTING; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOG; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LEISHMANIA CHAGASI; LEISHMANIA INFANTUM; NONHUMAN; PARASITE VIRULENCE; PHAGE DISPLAY; POLYMERASE CHAIN REACTION; TH1 CELL; TH2 CELL; VISCERAL LEISHMANIASIS; ANIMAL; BAGG ALBINO MOUSE; DOG DISEASE; FEMALE; IMMUNOLOGY; MALE; MOUSE; PARASITOLOGY; PEPTIDE LIBRARY; VETERINARY;

ANIMALIA; CANIS FAMILIARIS; LEISHMANIA INFANTUM; MURINAE; MUS;

ANIMALS; CHOLESTEROL; DOG DISEASES; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; LEISHMANIA INFANTUM; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; PEPTIDE LIBRARY; PEPTIDES; SPHINGOMYELINS;

EID: 84924981015     PISSN: None     EISSN: 17563305     Source Type: Journal    
DOI: 10.1186/s13071-015-0747-z     Document Type: Article

References (47)

1. Grimaldi Jr G, Tesh RB, McMahon-Pratt D. A review of the geographic distribution and epidemiology of leishmaniasis in the New World. Am J Trop Med Hyg. 1989;41(6):687-725.
2. Grimaldi Jr G, Tesh RB. Leishmaniases of the New World: current concepts and implications for future research. Clin Microbiol Rev. 1993;6(3):230-50.
3. Moreno J, Alvar J. Canine leishmaniasis: epidemiological risk and the experimental model. Trends Parasitol. 2002;18(9):399-405.
4. Cabrera OL, Munstermann LE, Cardenas R, Ferro C. PCR as a tool in confirming the experimental transmission of Leishmania chagasi to hamsters by Lutzomyia longipalpis (Diptera:Psychodidae). Biomedica: revista del Instituto Nacional de Salud. 2003;23(2):239-44.
5. Gradoni L, Maroli M, Gramiccia M, Mancianti F. Leishmania infantum infection rates in Phlebotomus perniciosus fed on naturally infected dogs under antimonial treatment. Med Vet Entomol. 1987;1(4):339-42.
6. Guarga JL, Moreno J, Lucientes J, Gracia MJ, Peribanez MA, Alvar J, et al. Canine leishmaniasis transmission: higher infectivity amongst naturally infected dogs to sand flies is associated with lower proportions of T helper cells. Res Vet Sci. 2000;69(3):249-53.
7. Madeira M, Barbosa-Santos E, Marzochi M. Experimental infection of canine peritoneal macrophages with visceral and dermotropic Leishmania strains. Mem Inst Oswaldo Cruz. 1999;94(5):645-8.
8. Marzochi MC, Coutinho SG, De Souza WJ, De Toledo LM, Grimaldi Junior G, Momen H, et al. Canine visceral leishmaniasis in Rio de Janeiro, Brazil. Clinical, parasitological, therapeutical and epidemiological findings (1977-1983). Mem Inst Oswaldo Cruz. 1985;80(3):349-57.
9. Madeira MF, Schubach A, Schubach TM, Pacheco RS, Oliveira FS, Pereira SA, et al. Mixed infection with Leishmania (Viannia) braziliensis and Leishmania (Leishmania) chagasi in a naturally infected dog from Rio de Janeiro, Brazil. Trans R Soc Trop Med Hyg. 2006;100(5):442-5.
10. Parra LE, Borja-Cabrera GP, Santos FN, Souza LO, Palatnik-de-Sousa CB, Menz I. Safety trial using the Leishmune vaccine against canine visceral leishmaniasis in Brazil. Vaccine. 2007;25(12):2180-6.
11. Fernandes AP, Costa MM, Coelho EA, Michalick MS, de Freitas E, Melo MN, et al. Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein. Vaccine. 2008;26(46):5888-95.
12. Manoutcharian K, Diaz-Orea A, Gevorkian G, Fragoso G, Acero G, Gonzalez E, et al. Recombinant bacteriophage-based multiepitope vaccine against Taenia solium pig cysticercosis. Vet Immunol Immunopathol. 2004;99(1-2):11-24.
13. Lanzillotti R, Coetzer TL. Phage display: a useful tool for malaria research? Trends Parasitol. 2008;24(1):18-23.
14. Hell RC, Amim P, de Andrade HM, de Avila RA, Felicori L, Oliveira AG, et al. Immunodiagnosis of human neurocysticercosis using a synthetic peptide selected by phage-display. Clin Immunol. 2009;131(1):129-38.
15. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-54.
16. Ey PL, Prowse SJ, Jenkin CR. Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. Immunochemistry. 1978;15(7):429-36.
17. Bonnycastle LL, Mehroke JS, Rashed M, Gong X, Scott JK. Probing the basis of antibody reactivity with a panel of constrained peptide libraries displayed by filamentous phage. J Mol Biol. 1996;258(5):747-62.
18. Ferrieres G, Villard S, Pugniere M, Mani JC, Navarro-Teulon I, Rharbaoui F, et al. Affinity for the cognate monoclonal antibody of synthetic peptides derived from selection by phage display. Role of sequences flanking the binding motif. Eur J Biochem/FEBS. 2000;267(6):1819-29.
19. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977;74(12):5463-7.
20. Laune D, Molina F, Ferrieres G, Villard S, Bes C, Rieunier F, et al. Application of the Spot method to the identification of peptides and amino acids from the antibody paratope that contribute to antigen binding. J Immunol Methods. 2002;267(1):53-70.
21. Frank D, Harland RM. Localized expression of a Xenopus POU gene depends on cell-autonomous transcriptional activation and induction-dependent inactivation. Development. 1992;115(2):439-48.
22. Gausepohl H, Boulin C, Kraft M, Frank RW. Automated multiple peptide synthesis. Pept Res. 1992;5(6):315-20.
23. de Machado Avila RA, Stransky S, Velloso M, Castanheira P, Schneider FS, Kalapothakis E, et al. Mimotopes of mutalysin-II from Lachesis muta snake venom induce hemorrhage inhibitory antibodies upon vaccination of rabbits. Peptides. 2011;32(8):1640-6.
24. Bethony JM, Simon G, Diemert DJ, Parenti D, Desrosiers A, Schuck S, et al. Randomized, placebo-controlled, double-blind trial of the Na-ASP-2 hookworm vaccine in unexposed adults. Vaccine. 2008;26(19):2408-17.
25. Alves CF, de Amorim IF, Moura EP, Ribeiro RR, Michalick MS, Kalapothakis E, et al. Expression of IFN-gamma, TNF-alpha, IL-10 and TGF-beta in lymph nodes associates with parasite load and clinical form of disease in dogs naturally infected with Leishmania (Leishmania) chagasi. Vet Immunol Immunopathol. 2009;128(4):349-58.
26. de Almeida FS, Leite RS, Ituassu LT, Almeida GG, Souza DM, Fujiwara RT, et al. Canine skin and conjunctival swab samples for the detection and quantification of Leishmania infantum DNA in an endemic urban area in Brazil. PLoS Negl Trop Dis. 2012;6(4):e1596.
27. Alvar J, Bashaye S, Argaw D, Cruz I, Aparicio P, Kassa A, et al. Kala-azar outbreak in Libo Kemkem, Ethiopia: epidemiologic and parasitologic assessment. Am J Trop Med Hyg. 2007;77(2):275-82.
28. Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine. 2012;30(11):1993-8.
29. Noya O, Patarroyo ME, Guzman F, de Alarcon NB. Immunodiagnosis of parasitic diseases with synthetic peptides. Curr Protein Pept Sci. 2003;4(4):299-308.
30. Gonzalez L, Boyle RW, Zhang M, Castillo J, Whittier S, Della-Latta P, et al. Synthetic-peptide-based enzyme-linked immunosorbent assay for screening human serum or plasma for antibodies to human immunodeficiency virus type 1 and type 2. Clin Diagn Lab Immunol. 1997;4(5):598-603.
31. Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol. 2002;2(11):845-58.
32. Melby PC. Vaccination against cutaneous leishmaniasis: current status. Am J Clin Dermatol. 2002;3(8):557-70.
33. Schijns VE, Lavelle EC. Trends in vaccine adjuvants. Expet Rev Vaccine. 2011;10(4):539-50.
34. Allison AG, Gregoriadis G. Liposomes as immunological adjuvants. Nature. 1974;252(5480):252.
35. Uemura K, Nicolotti RA, Six HR, Kinsky SC. Antibody formation in response to liposomal model membranes sensitized with N-substituted phosphatidylethanolamine derivatives. Biochemistry. 1974;13(8):1572-8.
36. Garcon NM, Six HR. Universal vaccine carrier. Liposomes that provide T-dependent help to weak antigens. J Immunol. 1991;146(11):3697-702.
37. Watson DS, Endsley AN, Huang L. Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine. 2012;30(13):2256-72.
38. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL. CD4∈+∈CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature. 2002;420(6915):502-7.
39. Baylor NW, Egan W, Richman P. Aluminum salts in vaccines-US perspective. Vaccine. 2002;20 Suppl 3:S18-23.
40. Frazer IH, Levin MJ. Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer. Current opinion in virology. 2011;1(4):268-79.
41. Hogenesch H. Mechanism of immunopotentiation and safety of aluminum adjuvants. Front Immunol. 2012;3:406.
42. Aimanianda V, Haensler J, Lacroix-Desmazes S, Kaveri SV, Bayry J. Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants. Trends Pharmacol Sci. 2009;30(6):287-95.
43. Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol. 2009;9(4):287-93.
44. Kool M, Fierens K, Lambrecht BN. Alum adjuvant: some of the tricks of the oldest adjuvant. J Med Microbiol. 2012;61(Pt 7):927-34.
45. MacLennan IC, Toellner KM, Cunningham AF, Serre K, Sze DM, Zuniga E, et al. Extrafollicular antibody responses. Immunol Rev. 2003;194:8-18.
46. Robinson HL, Amara RR. T cell vaccines for microbial infections. Nat Med. 2005;11(4 Suppl):S25-32.
47. Gregoriadis G. Immunological adjuvants: a role for liposomes. Immunol Today. 1990;11(3):89-97.